Kissei Pharmaceutical Co Ltd (Kissei) develops, manufactures, and sells pharmaceutical products in Japan. The company's portfolio includes medicines for urological, metabolic endocrinological, obstetrics and gynecological, nephrological, ophthalmic, and pulmonary system diseases and disorders.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Through R&D activities the company focuses on meeting the challenges of developing new drugs and providing them to people all over the world. The company's R&D focuses on the following key areas: urology, renal diseases and dialysis, and unmet medical needs. The company operates its R&D activities through four laboratories, which include: Central Research Laboratories, Safety Research Laboratories, Joetsu Chemical Laboratories and Pharmaceutical Laboratories. The company’s Central Research Laboratories focuses on three key main objectives which include, finding new drug substances for discovery research to search phase of development; conducting pharmacological research to examine the effectiveness of new drug substances, and conducting pharmacokinetic research for understanding properties of substances in vivo. The company’s Safety Research Laboratories focus on the safety aspect of new drug candidate compounds in accordance with national standards of Good Laboratory Practice. The company’s Joetsu Chemical Laboratories focuses on commercial production methods for new drug substances. The Pharmaceutical research laboratory focuses on the research of physical and chemical properties of the new drug compound. It also conducts research on the stability of new drug compounds. The company's major products in the research pipeline include CG0070, Linzagorix, Difelikefalin, KDT-3594, KSP-0243, Silodosin and Fostamatinib, among others. In FY2023, the company spent JPY10,391 million on its R&D activities, which as a percentage of its revenue stood at 15.4% and grew 0.3% YoY.